Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-12-27

FDA Approved: SOLIFENACIN SUCCINATE — Original Application (Aurobindo Pharma Limited)

View source ↗

Summary

FDA approves the original application for solifenacin succinate (generic) by Aurobindo Pharma Limited as a treatment option for overactive bladder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Solifenacin succinate (solifenacin)

Snippet

ORIG AP for SOLIFENACIN SUCCINATE (SOLIFENACIN SUCCINATE)